Abstract:
:A once-daily preservative-free fixed combination ophthalmic solution containing tafluprost 0.0015 % and timolol 0.5 % (hereafter referred to as tafluprost/timolol) [Taptiqom(®)] has been developed to lower intraocular pressure (IOP) whilst avoiding damage to the ocular surface associated with preservatives such as benzalkonium chloride. Tafluprost/timolol is available in various EU countries for the reduction of IOP in adults with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical monotherapy with β-adrenergic receptor antagonists or prostaglandin analogues and require a combination therapy, and who would benefit from preservative-free eye drops. In two multinational, phase III studies, tafluprost/timolol was superior to monotherapy with either preservative-free tafluprost 0.0015 % once daily or preservative-free timolol 0.5 % twice daily, and noninferior to concomitant therapy with preservative-free tafluprost 0.0015 % once daily plus preservative-free timolol 0.5 % twice daily in lowering IOP in adults with open-angle glaucoma or ocular hypertension. Tafluprost/timolol was well tolerated in these studies, with a tolerability profile consistent with that of its individual components and with no new adverse reactions observed. Thus, preservative-free fixed combination tafluprost/timolol is an effective treatment option for the reduction of IOP in adults with open-angle glaucoma or ocular hypertension, providing a useful alternative for those patients who would benefit from preservative-free eye drops.
journal_name
Drugsjournal_title
Drugsauthors
Hoy SMdoi
10.1007/s40265-015-0476-9subject
Has Abstractpub_date
2015-10-01 00:00:00pages
1807-13issue
15eissn
0012-6667issn
1179-1950pii
10.1007/s40265-015-0476-9journal_volume
75pub_type
杂志文章,评审相关文献
DRUGS文献大全abstract::Tipranavir (Aptivus) is a selective nonpeptidic HIV-1 protease inhibitor (PI) that is used in the treatment of treatment-experienced adults with HIV-1 infection. Tipranavir is administered orally twice daily and must be given in combination with low-dose ritonavir, which is used to boost its bioavailability. The durab...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200868100-00006
更新日期:2008-01-01 00:00:00
abstract::Bisoprolol is a beta 1-adrenoceptor antagonist with no partial agonist (intrinsic sympathomimetic) activity or membrane stabilising (local anaesthetic) activity. The oral bioavailability of bisoprolol is high (90%) and the drug has a long elimination half-life which allows once-daily administration; in addition, it is...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198836030-00002
更新日期:1988-09-01 00:00:00
abstract::For almost half a century, the first-line treatment for ovulation induction in cases of anovulation, unexplained infertility, or mild male factor has been clomifene (clomiphene citrate). Clomifene is an effective and safely used oral agent, but is known to have relatively common antiestrogenic endometrial and cervical...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666170-00001
更新日期:2006-01-01 00:00:00
abstract::The concept of balanced analgesia was introduced to improve analgesic efficacy and reduce adverse effects. A large amount of clinical data has documented improved analgesia by combining different analgesics, but data on reducing adverse effects are inconclusive. Balanced analgesia should be used whenever possible, and...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199958050-00002
更新日期:1999-11-01 00:00:00
abstract::Lefamulin is a novel oral and intravenous (IV) pleuromutilin developed as a twice-daily treatment for community-acquired bacterial pneumonia (CABP). It is a semi-synthetic pleuromutilin with a chemical structure that contains a tricyclic core of five-, six-, and eight-membered rings and a 2-(4-amino-2-hydroxycyclohexy...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01443-4
更新日期:2020-11-28 00:00:00
abstract::The optimal treatment of pain requires an understanding of the mechanisms involved. Pain is a sensory end-point that can be generated by a number of dissimilar processes. Consequently, the concept of treating pain as a unitary symptom is obsolete. The mechanisms responsible for specific types of pain need to be unders...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199400475-00003
更新日期:1994-01-01 00:00:00
abstract::Levetiracetam (Keppra®, E Keppra®) is an established second-generation antiepileptic drug (AED). Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial onset seizu...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11204490-000000000-00000
更新日期:2011-03-05 00:00:00
abstract::Acitretin (etretin), a second generation monoaromatic retinoid for use in the treatment of severe psoriasis and other dermatoses, is the major active metabolite of etretinate and possesses a similar therapeutic index; i.e. a similar ratio of clinical efficacy to adverse effects. When used alone at a maintenance dosage...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199243040-00010
更新日期:1992-04-01 00:00:00
abstract::Nausea and vomiting continue to be critical problems in cancer chemotherapy, although considerable progress has been made toward understanding the neuropharmacological mechanisms of vomiting and how chemotherapeutic agents and antiemetics affect these mechanisms. The principles of behavioural psychology have also been...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198734010-00005
更新日期:1987-07-01 00:00:00
abstract::Trifluridine/tipiracil (Lonsurf(®)) is a novel, orally active, antimetabolite agent comprised of trifluridine, a thymidine-based nucleoside analogue, and tipiracil, a potent thymidine phosphorylase inhibitor. Trifluridine is incorporated into DNA via phosphorylation, ultimately inhibiting cell proliferation. Tipiracil...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-016-0633-9
更新日期:2016-09-01 00:00:00
abstract::The selective once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (Lyxumia(®)) is under development with Sanofi for the treatment of type 2 diabetes mellitus. Lixisenatide belongs to a class of GLP-1 compounds designed to mimic the endogenous hormone GLP-1. Native GLP-1 stimulates insulin...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-013-0033-3
更新日期:2013-03-01 00:00:00
abstract::Levocabastine is a potent and selective histamine H1-receptor antagonist which has been evaluated as a topical treatment (nasal spray and/or eyedrops) for allergic rhinitis and/or conjunctivitis. Data available at the time of the previous review in Drugs, together with more recent results, have clearly demonstrated th...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199550060-00009
更新日期:1995-12-01 00:00:00
abstract::Insulin degludec (Tresiba(®)) is an ultra-long-acting insulin analogue that is also available as a coformulation with rapid-acting insulin aspart (insulin degludec/insulin aspart) [Ryzodeg(®)]. Insulin degludec has a flat, stable glucose-lowering profile with a duration of action of >42 h, and less within-patient day-...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-013-0051-1
更新日期:2013-05-01 00:00:00
abstract::Emicizumab (Hemlibra®), a recombinant, humanized, bispecific monoclonal antibody, restores the function of missing activated factor VIII (FVIII) by bridging FIXa and FX to facilitate effective haemostasis in patients with haemophilia A. Subcutaneous emicizumab is approved in several countries, including in the USA and...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01200-2
更新日期:2019-10-01 00:00:00
abstract::The pharmacokinetics of cefoperazone in normal subjects, and in patients with hepatic and renal dysfunction are reviewed. After intravenous administration of 2 g of cefoperazone, levels in serum ranged from 202 to 375 microgram/ml depending on the period of drug administration. After intramuscular injection of 2 g of ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198100221-00010
更新日期:1981-01-01 00:00:00
abstract::Alterations of skin and hair pigmentation are important features that have warranted treatment from ancient history on up to modern time. In some cultures, even today patients with vitiligo are regarded as social outcasts and are affected considerably both emotionally and physically. This article presents current opti...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200464010-00006
更新日期:2004-01-01 00:00:00
abstract::Letermovir (Prevymis™) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH. Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and diseas...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-017-0860-8
更新日期:2018-01-01 00:00:00
abstract::Sodium-glucose co-transporter 2 (SGLT2) inhibitors are glucose-lowering drugs that reduce plasma glucose levels by inhibiting glucose and sodium reabsorption in the kidneys, thus resulting in glucosuria. Their effects consequently include reductions in HbA1c, blood glucose levels, and blood pressure, but also reductio...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-1057-0
更新日期:2019-02-01 00:00:00
abstract::Glipizide is a 'second generation' oral hypoglycaemic agent similar in potency to glibenclamide. It is completely absorbed after oral administration and has a rapid onset of action, but the duration of its hypoglycaemic effect is shorter than that of glibenclamide. It is rapidly metabolised to inactive metabolites whi...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-197918050-00001
更新日期:1979-11-01 00:00:00
abstract::Azacitidine (Vidaza) is a pyrimidine nucleoside analogue of cytidine. Subcutaneous azacitidine was recently approved in the EU for the treatment of adults who are not eligible for haematopoietic stem cell transplantation and who have intermediate-2-risk or high-risk myelodysplastic syndromes (MDS) [according to Intern...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11202840-000000000-00000
更新日期:2009-01-01 00:00:00
abstract::Chenodeoxycholic acid (chenic acid; CDCA) is 1 of the 3 major biliary bile acids in man. When administered in pharmacological doses it causes a decrease in cholesterol saturation of bile, which in turn may lead to gradual dissolution of cholesterol gallstones. The stone dissolution rate during CDCA therapy has varied ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198121020-00002
更新日期:1981-02-01 00:00:00
abstract::Cibenzoline is a class I antiarrhythmic drug with limited class III and IV activity which can be administered orally or intravenously. An elimination half-life of about 8 to 12 hours permits twice daily administration, although age and renal function must be considered when determining dosage. Cibenzoline has some act...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199243050-00008
更新日期:1992-05-01 00:00:00
abstract:UNLABELLED:Zolpidem is an imidazopyridine agent that is indicated for the short term (< or = 4 weeks) treatment of insomnia (recommended dosage 10 mg/day in adults and 5 or 10 mg/day in the elderly or patients with hepatic impairment). Data have shown that the hypnotic efficacy of zolpidem is generally comparable to th...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200059040-00014
更新日期:2000-04-01 00:00:00
abstract::Although vasodilator drugs are of proven worth in the management of patients with severe heart failure, a useful system of classification of vasodilator drugs has not yet been devised. The traditional system of classification based on the dominant arterial and/or venous sites of action as determined by limb plethysmog...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198224010-00003
更新日期:1982-07-01 00:00:00
abstract::Orlistat is a nonsystemically acting gastric and pancreatic lipase inhibitor that limits the absorption of dietary fat. A retrospective pooled analysis of three 2-year, double-blind, randomised, placebo-controlled trials involving patients with obesity revealed that orlistat recipients were more likely to experience a...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200161140-00011
更新日期:2001-01-01 00:00:00
abstract::Pharmacological treatment of hypertension can, cause clinically significant alterations in endocrine function and glucose homeostasis. The aim of this study was to investigate the antihypertensive efficacy and the influence on carbohydrate metabolism of carvedilol and metoprolol in non-insulin-dependent diabetics with...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-198800366-00023
更新日期:1988-01-01 00:00:00
abstract::25 patients have been included in a randomised trial aimed to compare prehospital and hospital administration of anisoylated plasminogen streptokinase activator complex (AP-SAC). Patients were first seen, at home, by a noncardiologist doctor working in a mobile-care unit and were then evaluated for entry into the stud...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-198700333-00042
更新日期:1987-01-01 00:00:00
abstract::Despite advances in the understanding of the mechanism of cerebral injury during focal ischaemia, the best treatment of cerebral ischaemia is still prevention. The pathophysiological mechanisms that contribute to cerebral ischaemia are discussed relative to the many therapeutic interventions that have been attempted. ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198835040-00005
更新日期:1988-04-01 00:00:00
abstract::Sore throats are most commonly due to infections, many of which are viral and do not require specific treatment. Symptoms and signs of the common cold, influenza or croup, the occurrence of conjunctivitis in some adenoviral infections, generalised lymphadenopathy and splenomegaly in glandular fever or the presence of ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199040060-00007
更新日期:1990-12-01 00:00:00
abstract::Alprazolam is a triazolobenzodiazepine which is related to diazepam and other 1,4-benzodiazepines, and has a similar pharmacological profile. Relative to the newer benzodiazepines, alprazolam has an intermediate half-life of 10 to 12 hours in healthy young subjects. In placebo-controlled and double-blind comparative t...
journal_title:Drugs
pub_type: 临床试验,杂志文章,评审
doi:10.2165/00003495-198427020-00002
更新日期:1984-02-01 00:00:00